Predict your next investment

Incubator/Accelerator
neurolaunch.org

See what CB Insights has to offer

Investments

12

About NeuroLaunch

The NeuroLaunch accelerator program is a 90 day program for early and growth stage neuro-related start-up companies. Its focus areas include neuro-gaming and neuroplasticity, brain-computer interfacing, neuro-related computing (machine learning/artificial intelligence), neuroinformatics, neuro-imaging, and medical device/pharmaceutical/diagnostic applications.

NeuroLaunch Headquarter Location

75 5th St. NW #333

Atlanta, Georgia, 30308,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest NeuroLaunch News

NeuroLaunch, World's First Neuroscience Startup Accelerator, Announces Its Next Demo Day

Dec 15, 2015

SAN FRANCISCO, CA--(Marketwired - Aug 4, 2015) - NeuroLaunch , the world's first startup accelerator program for neuroscience companies, has announced the schedule for its second Demo Day on Monday, August 24, 2015. NeuroLaunch Demo Day is a targeted investor-oriented showcase for the five startups completing the NeuroLaunch accelerator program, and will also feature 20 poster presentations from other top neuro-startups from around the world, as well as a panel with thought leaders on "Investment Horizons in Neuroscience. " About NeuroLaunch Demo Day (Summer 2015 Cohort) August 24, 2015, 3:30 PM-8 PM, including cocktail reception Atlanta Tech Village, 3423 Piedmont Road NE, Atlanta, GA 30305 Register: http://demoday.neurolaunch.com Capacity for Demo Day is limited; early registration is recommended. Early bird pricing, with a discount of $200, is available until August 10. Accredited investors should contact NeuroLaunch for a complimentary registration code. As of August 2015, NeuroLaunch has 11 neuroscience startup companies in its portfolio . The five NeuroLaunch portfolio companies completing the current batch were selected from over 50 applications worldwide and include: 45 Degrees Health: Technology platform for improving patient experience and outcomes through data driven concussion management. Atanse: Develops and sells neurosurgical instruments that allow delivery of biotechnology-based therapies with greater precision and reduced brain trauma. MonitorMed Solutions: Accessible shunt technology that provides hydrocephalus patients with the ability to monitor shunt performance using a mobile device, leading to improved lifestyle for patients and reducing unnecessary medical procedures. Neurish: Location-based mobile social network to improve the lives of people affected by epilepsy and other neurological disorders. Zyrobotics: Creating accessible technologies that engage and empower children with motor disabilities to enhance their quality of life. "The portfolio companies in this batch of NeuroLaunch represent some of the most promising neuroscience-related startups we have identified from around the world," said Christopher Klaus, NeuroLaunch co-founder and serial entrepreneur. NeuroLaunch companies are given access to seed funding, world-class mentors, a 90-day tailored curriculum for business model validation, strategic partnerships, and direct introductions to investors. NeuroLaunch currently conducts operations in three cities: Boston, San Francisco, and Atlanta. The current group of five startups represents the program's second batch of companies, of which two are headquartered in Boston, one in Virginia, and two in Atlanta. "NeuroLaunch marks an exciting new era of joining lean startup culture with neuroscience," said Dr. Jordan Amadio, NeuroLaunch co-founder and resident physician in neurosurgery at Emory University. "We have introduced a novel method for accelerating innovations related to the brain and nervous system. " About NeuroLaunch NeuroLaunch is the leading accelerator program for neuroscience startup companies. We are the first organization to apply the data-driven startup accelerator method, which has risen to global prominence as a model for technology entrepreneurs, to neuroscience. By removing barriers for the most promising neuroscience startups, we sustain the world's most robust community of early-stage neuroscience innovators, investors, and thought leaders. NeuroLaunch currently conducts operations in three cities: Boston, Atlanta, and San Francisco. Learn more about NeuroLaunch at: www.NeuroLaunch.com ; Twitter @NeuroLaunch; Facebook.com/NeuroLaunch. Contact Information

NeuroLaunch Investments

12 Investments

NeuroLaunch has made 12 investments. Their latest investment was in Zyrobotics as part of their Seed on August 8, 2015.

CBI Logo

NeuroLaunch Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/5/2015

Seed

Zyrobotics

$0.02M

Yes

1

8/5/2015

Seed

Neurish

$0.02M

Yes

1

8/5/2015

Seed

MonitorMed Solutions

$0.02M

Yes

1

8/5/2015

Seed

Subscribe to see more

$99M

Subscribe to see more

10

8/5/2015

Seed

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/5/2015

8/5/2015

8/5/2015

8/5/2015

8/5/2015

Round

Seed

Seed

Seed

Seed

Seed

Company

Zyrobotics

Neurish

MonitorMed Solutions

Subscribe to see more

Subscribe to see more

Amount

$0.02M

$0.02M

$0.02M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

1

10

10

NeuroLaunch Team

2 Team Members

NeuroLaunch has 2 team members, including undefined undefined, undefined.

Name

Work History

Title

Status

Christopher W Klaus

Founder

Current

Anish Joseph

Founder

Former

Name

Christopher W Klaus

Anish Joseph

Work History

Title

Founder

Founder

Status

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.